PHILADELPHIA, PA – iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today approval from the U.K. Medicines & Healthcare products Regulatory Agency (MHRA) of the company’s Clinical Trial Authorisation...
treatment News
PHILADELPHIA, PA — iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ECUR-506, the company’s...
PHILADELPHIA, PA — iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders with significant unmet need, today announced that additional data from the ongoing OTC-HOPE clinical trial evaluating its candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency...
BASKING RIDGE, NJ AND RAHWAY, NJ – Results from the IDeate-Lung01 Phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). These data were presented today during a late-breaking presentation (OA06.03) and included as part of the...
BASKING RIDGE, NJ AND RAHWAY, NJ – Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Ifinatamab deruxtecan is a specifically...
Copenhagen, Denmark – After five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% of patients with ankylosing spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ASAS partial remission. Moreover, at five years, 78.4% of AS patients had no arthritis and 84.9% had no enthesitis...
POTOMAC, Md. — IGC Pharma, Inc. provides details on its drug candidate TGR-63, which targets amyloid-beta plaque and can potentially improve Alzheimer’s disease treatment in a significant manner. A key pathological marker of Alzheimer’s disease is the formation of abnormal clusters of protein fragments called amyloid-beta (Aβ) that deposit as...
Barcelona, Spain – Researchers from the Germans Trias i Pujol Research Institute (IGTP) have made progress in exploring potential treatments for skin tumours associated with neurofibromatosis type 1. Their findings in cell models have been published in the journal JCI Insight. Neurofibromatosis type 1 is a rare genetic disorder that...
DORVAL, QC – Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris® (canakinumab) for the treatment of active Still’s disease, including adult-onset Still’s disease (AOSD)[1]. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications[2]....
San Diego — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, begins a monthlong celebration of its 25th anniversary. A quarter-century after its founding in San Diego in April 1998, the company is commemorating its anniversary by celebrating its employees, customers, and entire stakeholder ecosystem,...